RNA-binding protein gene NOP58 exhibits crucial prognostic and therapeutic value in Ewing sarcoma

Yang Geng, Lu Yang, Rui Shao, Tiantong Xu, Lilong ZhangHereditas 2025 · DOI

Abstract

Collectively, downregulation of NOP58 could inhibit the proliferation and migration of EwS cells in vitro and reduce murine xenograft tumor growth in vivo. These findings identified NOP58 as a promising regulator of EwS tumorigenesis, suggesting it may serve as a potential therapeutic target for EwS treatment.

Introduction

Ewing sarcoma (EwS) is a highly aggressive bone and soft tissue tumor that primarily affects children and adolescents. Despite intensive treatment regimens involving chemotherapy, surgery, and radiation, the prognosis for metastatic or recurrent cases remains poor. A significant challenge in treating EwS is the lack of FDA-approved molecularly targeted therapies or effective immunotherapies.

While the disease is characterized by the EWSR1-FLI1 fusion protein—itself an RNA-binding protein (RBP)—the broader role of other RBPs in EwS progression is not well understood. RBPs are critical regulators of post-transcriptional gene expression, including splicing, transport, and translation. Dysregulation of these processes is a known driver of oncogenesis. This study aims to identify novel RBP-related biomarkers and therapeutic targets in EwS.

Methods

The study employed a multi-stage approach combining bioinformatics with experimental validation.

Bioinformatics Analysis

Researchers analyzed transcriptomic datasets from the Gene Expression Omnibus (GEO), including GSE68776, GSE45544, and GSE17674, to identify differentially expressed genes (DEGs) between EwS and normal tissues. These DEGs were intersected with a comprehensive list of known RBPs. A Protein-Protein Interaction (PPI) network was constructed to identify hub genes, and univariate Cox regression was used to determine the prognostic significance of these genes. Immune infiltration was assessed using CIBERSORT and xCell algorithms.

Experimental Validation

  • In vitro: NOP58 expression was validated in human EwS cell lines (A673, RD-ES, SK-N-MC). Functional assays, including CCK-8 (proliferation), Transwell (migration), and flow cytometry (apoptosis/cell cycle), were performed following shRNA-mediated knockdown of NOP58.
  • In vivo: The impact of NOP58 knockdown on tumor growth was evaluated using a murine xenograft model, monitoring tumor volume over 15 days.

Key Results

The integrated analysis identified 179 differentially expressed RBP genes. Among these, NOP58 emerged as a central hub gene significantly upregulated in EwS.

Identification and functional enrichment analysis of differentially expressed RNA-binding protein genes in Ewing sarcoma.

Prognostic Significance

High expression of NOP58 was found to be an independent predictor of poor overall survival. Time-dependent ROC analysis showed AUC values of 0.64, 0.71, and 0.76 for 1-, 3-, and 5-year survival, respectively, indicating its potential as a robust prognostic biomarker.

Functional Impact

Knockdown of NOP58 significantly impaired the oncogenic phenotype of EwS cells. In vitro experiments demonstrated reduced proliferation and migration, alongside G0/G1 phase cell cycle arrest and increased apoptosis. These findings were mirrored in vivo, where NOP58 depletion led to a dramatic reduction in xenograft tumor growth.

Pathway and Immune Modulation

Gene Set Enrichment Analysis (GSEA) indicated that NOP58 may drive EwS progression by activating pathways such as JAK-STAT, MAPK, and NF-kappa B. Furthermore, high NOP58 expression correlated with an immunosuppressive microenvironment, characterized by higher PD-1 levels and lower immune scores.

Discussion

This study highlights NOP58, a core component of small nucleolar ribonucleoproteins (snoRNPs), as a critical vulnerability in Ewing sarcoma. Beyond the primary fusion protein, the broader RNA-processing machinery appears to be hijacked to support tumor growth and immune evasion.

While these results are promising, the study is limited by the relatively small sample sizes inherent in rare pediatric cancer research and the reliance on transcriptomic data. Future work should focus on validating these findings in larger clinical cohorts and exploring the precise biochemical mechanisms by which NOP58-mediated 2'-O-ribose methylation influences downstream signaling. Ultimately, NOP58 represents a potential target for novel therapeutic strategies, such as nanoparticle-delivered RNA interference.

Summary updated

Abstract

Collectively, downregulation of NOP58 could inhibit the proliferation and migration of EwS cells in vitro and reduce murine xenograft tumor growth in vivo. These findings identified NOP58 as a promising regulator of EwS tumorigenesis, suggesting it may serve as a potential therapeutic target for EwS treatment.
BibTeX
@inproceedings{geng2025rna,
  author = {Yang Geng and Lu Yang and Rui Shao and Tiantong Xu and Lilong Zhang},
  title = {{RNA-binding protein gene NOP58 exhibits crucial prognostic and therapeutic value in Ewing sarcoma}},
  booktitle = {Hereditas},
  year = {2025},
  doi = {10.1186/s41065-025-00440-5},
}
Figure